GRML Stock Catalyst: Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis

Klotho Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for KLTO-202, a novel therapeutic candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS). The designation was granted based on the potential of KLTO-202 to address a significant unmet medical need in the ALS patient population.

Orphan Drug Designation provides certain benefits to Klotho Neurosciences, including tax credits for clinical trials, prescription drug user fee waivers, and eligibility for seven years of market exclusivity upon FDA approval. The company is currently advancing KLTO-202 through preclinical and clinical development stages to evaluate its safety and efficacy in treating ALS.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.